A randomized, double-blind, solifenacin succinate versus placebo control, phase 4, multicenter study evaluating urinary continence after robotic assisted radical prostatectomy.

Author(s): Bianco FJ(1), Albala DM(2), Belkoff LH(3), Miles BJ(4), Peabody JO(5), He W(6), Bradt JS(6), Haas GP(6), Ahlering TE(7).

Affiliation(s): Author information: (1)Urological Research Network, Miami, Florida. (2)Associated Medical Professionals, Syracuse, New York. (3)Urologic Consultants of Southeastern Pennsylvania, Bala Cynwyd, Pennsylvania. (4)Houston Methodist Research Institute, Houston, Texas. (5)Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan. (6)Astellas, Northbrook, Illinois. (7)UC Irvine, Orange, California.

Publication date & source: 2015, J Urol. , 193(4):1305-10

PURPOSE: Bladder dysfunction influences recovery of urinary continence after radical prostatectomy. We performed a multicenter, randomized, double-blind study evaluating solifenacin vs placebo on return to continence in patients who were still incontinent 7 to 21 days after catheter removal after robot-assisted radical prostatectomy. MATERIALS AND METHODS: A wireless personal digital assistant was given to patients the day of catheter removal. Encrypted answers were transmitted daily to dedicated servers. After a 7 to 21-day treatment-free washout period, patients requiring 2 to 10 pads per day for 7 consecutive days were randomized (1:1) to 5 mg solifenacin daily or placebo. The primary end point was time from first dose to continence defined as 0 pads per day or a dry security pad for 3 consecutive days. Secondary end points included proportion of patients continent at end of study, average change in pads per day number and quality of life assessments. RESULTS: A total of 1,086 screened patients recorded personal digital assistant information. Overall 640 patients were randomized to solifenacin vs placebo and 17 failed to take medication. There was no difference in time to continence (p=0.17). Continence was achieved by study end in 91 of 313 (29%) vs 66 of 309 (21%), respectively (p=0.04). Pads per day change from baseline was -3.2 and -2.9, respectively (p=0.03). Dry mouth was the only common adverse event seen in 6.1% and 0.6%, respectively. Constipation rates were similar. The overall rate of continence in the entire population from screening to end of study was 73%. CONCLUSIONS: There was no effect on primary outcome but some secondary end points benefited the solifenacin arm. The study provides level 1B clinical evidence for continence outcomes after robot-assisted radical prostatectomy.